Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Lanqin Granules for acute upper respiratory tract infection in children
ChiCTR2300069186Phase 4Not yet recruiting
- Sponsor
- Yunnan Provincial Hospital of Traditional Chinese Medicine
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Lanqin Oral Liquid in upper respiratory infection (URI) (2 arms), sponsored by Yunnan Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Time for sore throat to disappear. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
Lanqin Oral Liquid
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on ChiCTR2300069186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069186.